/Investor DB

Pureos Bioventures — 2025 Investments

2 investments dated 2025 · listed companies and verified rows first · show all

AnaCardioanacardio.comSeries A · Jan 2025 · $18M✓ verified

AnaCardio is a Swedish clinical-stage biopharmaceutical company developing novel drugs to treat heart failure, with its lead program AC01 in phase 1b/2a clinical development.

BiotechHealthtechMedical DevicesStockholm, SE

Lars H. Lund(Founder)

Co-investors3B Future Health FundIndustrifondenNovo HoldingsSound Bioventures

PulseSight Therapeuticspulsesight.cominSeed · Feb 2025✓ verified

PulseSight Therapeutics develops non-viral, plasmid-based gene therapies delivered via a proprietary electro-transfection system into the ciliary muscle to treat severe retinal diseases causing blindness.

BiotechHealthtechMedical Devices

Co-investors+ND Capital

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.